Explore the impact of type 2 inflammation and airway remodeling on lung function decline in asthma.

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

Navigate through this interactive infographic to learn more about why lung function is important to monitor in pediatric patients with asthma and the noninvasive procedures that are available for implementation in clinical practice.
Join Drs. Wanda Phipatanakul and Theresa Guilbert as they discuss the importance of routine lung function assessment in pediatric asthma patients.

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

Join Dr. Celeste Porsbjerg as she explores the mechanisms underlying mucus plugging development as mucociliary clearance. She explains how type 2 cytokines—particularly IL-13—impair this clearance mechanism, leading to mucus plugging, and worsened asthma outcomes.

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.